The role of entecavir in the treatment of chronic hepatitis B

References

• BrunelleMNJacquardACPichoudCSusceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovirHepatology2005411391815915463
   PubMed Web of Science ®Google Scholar
• ChangTTGishRGHadziyannisSJA dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patientsGastroenterology2005129119820916230074
   PubMed Web of Science ®Google Scholar
• ChangTTGishRGDe ManRA comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis BN Engl J Med2006a35410011016525137
   PubMed Web of Science ®Google Scholar
• ChangTTChaoYCKaymakoglouSEntecavir maintained virologic suppression through 3 years of treatment in antiviral-naïve HBeAg(+) patients (ETV 022/901)Hepatology2006b44229A
   Web of Science ®Google Scholar
• ColonnoRJRoseREBaldickCJHigh barrier of resistance results in no emergence of entecavir resistance in nucleoside-naïve subjects during the first two years of therapyJ Hepatol2006a44S182
   Web of Science ®Google Scholar
• ColonnoRJRoseREPokornowskiKAssessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patientsHepatology2006b44229A
   Web of Science ®Google Scholar
• CooksleyHHouJLVitekLImpact of nucleoside treatment on antiviral T-cell reactivity in chronic hepatitis B: major differences depending on early viral suppression, HBeAg status and HBV genotypeHepatology200644547A
   Web of Science ®Google Scholar
• De ManRALeoniekeMMWNevensFSafety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infectionHepatology2001345788211526545
   PubMed Web of Science ®Google Scholar
• Di MarcoVMarzanoALamperticoPClinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to LamivudineHepatology2004408839115382125
   PubMed Web of Science ®Google Scholar
• DienstangJLSchiffERWrightTLLamivudine as initial treatment for chronic hepatitis B in the United statesN Engl J Med199934112566310528035
   PubMed Web of Science ®Google Scholar
• DienstagJLGoldiRDHeathcoteEJHistological outcome during long-term lamivudine therapyGastroenterology20031241051712512035
   PubMed Web of Science ®Google Scholar
• FungSKAndreonePHanSHAdefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationJ Hepatol2005439374316168522
   PubMed Web of Science ®Google Scholar
• FungSKChaeHBFontanaRJVirological response and resistance to adefovir in patients with chronic hepatitis BJ Hepatol2006442839016338024
   PubMed Web of Science ®Google Scholar
• GishRGChangTTDe ManREntecavir results in substantial virologic and biochemical improvement and HBeAg seroconvertion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (Study ETV-022)Hepatology200542267A268A
   Web of Science ®Google Scholar
• HadziyannisSJBramouTMakrisAInterferon a-2b treatment of HBeAg negative/serum HBV-DNA positive chronic active hepatitis type BJ Hepatol199011Suppl 1S113362079567
   PubMed Web of Science ®Google Scholar
• HadziyannisSJTassopoulosNCHeathcoteEJAdefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitisBN Engl J Med2003348800712606734
   PubMed Web of Science ®Google Scholar
• HadziyannisSJTassopoulosNCHeathcoteEJLong-term therapy with Adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis BN Engl J Med2005a35226738115987916
   PubMed Web of Science ®Google Scholar
• HadziyannisSJTassopoulosNCChangTTLong-term Adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapyHepatology2005b42754A
   Google Scholar
• HadziyannisSJTassopoulosNCHeathcoteEJLong-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 yearsGastroenterology200613117435117087951
   PubMed Web of Science ®Google Scholar
• LaiCLChienRNLeungNWYA one year trial of lamivudine for chronic hepatitis BN Engl J Med19983396189654535
   PubMed Web of Science ®Google Scholar
• LaiCLRosmawatiMLaoJEntecavir is superior than lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infectionGastroenterology20021231831812454840
   PubMed Web of Science ®Google Scholar
• LaiCLLimSGBrownNAA dose-finding study of once-daily oral Telbivudine in HBeAg-positive patients with chronic hepatitis B virus infectionHepatology2004407192615349912
   PubMed Web of Science ®Google Scholar
• LaiCLLeungNTeoEKA 1-year trial of Telbivudine, Lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis BGastroenterology2005a1295283616083710
   PubMed Web of Science ®Google Scholar
• LaiCLGaneELiawYFTelbivudine (LDT) vs. Lamivudine for chronic hepatitis B: first-year results from the international phase III globe trialHepatology2005b42748A
   PubMed Web of Science ®Google Scholar
• LaiCLGaneEHsuCWTwo-years results from the globe trial in patients with hepatitis B: greated clinical and antiviral efficacy for telbivudine (LDT) vs lamivudineHepatology2006a44222A
   Google Scholar
• LaiCLShouvalDLokASEntecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis BN Engl J Med2006b35410112016525138
   PubMed Web of Science ®Google Scholar
• LamperticoPViganoMManentiEFive years of sequential LAM to LAM +ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinomaHepatology200542582A
   Web of Science ®Google Scholar
• LamperticoPViganoMIavaroneMLow rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 yearsHepatology200644556A
   Web of Science ®Google Scholar
• LauGKKPiratvisuthTLuoKXPeginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis BN Engl J Med200535226829515987917
   PubMed Web of Science ®Google Scholar
• LeeWMHepatitis B virus infectionN Engl J Med19973371733459392700
   PubMed Web of Science ®Google Scholar
• LeungNWYLaiCLChangTTExtended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapyHepatology20013315273211391543
   PubMed Web of Science ®Google Scholar
• LiawYFLeungNWYChangTTEffects of extended lamivudine therapy in Asian patients with chronic hepatitis BGastroenterology20001191728010889166
   PubMed Web of Science ®Google Scholar
• LiawYFSungJJYChowWCLamivudine for patients with chronic hepatitis B and advanced liver diseaseN Engl J Med200435115213115470215
   PubMed Web of Science ®Google Scholar
• LokASHeathcoteEJHoofnagleJHManagement of hepatitis B: 2000 summary of a workshopGastroenterology200112018285311375963
   PubMed Web of Science ®Google Scholar
• LokASFLaiCLLeungNLong-term safety of Lamivudine treatment in patients with chronic hepatitis BGastroenterology200312517142214724824
   PubMed Web of Science ®Google Scholar
• MaddreyWCHepatitis B: an important public health issueJ Med Virol200061362610861647
   PubMed Web of Science ®Google Scholar
• ManesisEHadziyannisSInteferon α treatment and retreatment of hepatitis B e negative chronic hepatitis BGastroenterology2001321101911438498
   PubMed Web of Science ®Google Scholar
• MarcellinPChangTTLimSGAdefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitisBN Engl J Med20033488081612606735
   PubMed Web of Science ®Google Scholar
• MarcellinPLauGKKBoninoFPeginterferon alfa-2a alone, lamivudine alone and the two combination in patients with HBeAg-negative chronic hepatitis BN Engl J Med200435112061715371578
   PubMed Web of Science ®Google Scholar
• MarcellinPChangTTLimSGIncreasing serologic, virologic and biochemical response over time to Adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patientsJ Hepatol2005422S312
   Google Scholar
• MarcellinPLauGKKFarciPThe majority of patients with HBeAg-negative chronic hepatitis B treated with Peginterferon alpha-2a (40KD) [PEGASYS] sustain responses 2 years post-treatmentJ Hepatol2006442S275
   Web of Science ®Google Scholar
• NiederaouCHeintgesTLangeSLong term follow up of HBeAg positive patients treated with interferon alpha for chronic hepatitis BN Engl J Med1996334142278618580
   PubMed Web of Science ®Google Scholar
• PapatheodoridisGVManesisEHadziyannisSJThe long-term outcome of interferon-a treated and untreated patients with HBeAg-negative chronic hepatitis BJ Hepatol2001343061311281561
   PubMed Web of Science ®Google Scholar
• PapatheodoridisGVDimouELarasACourse of virological breakthroughs under long-term lamivudine in HBeAg negative precore mutant HBV liver diseaseHepatology2002362192612085368
   PubMed Web of Science ®Google Scholar
• PapatheodoridisGVDimouEDimakopoulosKOutcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudineHepatology200542121915962291
   PubMed Web of Science ®Google Scholar
• PetersMGHannHWMartinPAdefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitisBGastroenterology20041269110114699491
   PubMed Web of Science ®Google Scholar
• RaptiINDimouEMitsoulaPHadziyannisSJCombination of adefovir dipivoxil with lamivudine vs adefovir alone in lamivudine-resistant HBeAg-negative chronic hepatitis B patientsHepatology2007453071317256746
   PubMed Web of Science ®Google Scholar
• SchiffELeeWMChaoYCEfficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis BHepatology200542583A
   Web of Science ®Google Scholar
• ShermanMYurdaydinCSollanoJEntecavir for the treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis BGastroenterology200613020394916762627
   PubMed Web of Science ®Google Scholar
• ShouvalDHatzisGKitisGContinued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) hepatitis B patients (Study ETV-027)J Hepatol200644S182
   Web of Science ®Google Scholar
• TassopoulosNCVolpesRPastoreGEfficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis BHepatology1999298899610051494
   PubMed Web of Science ®Google Scholar
• TenneyDJLevineSMRoseREClinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudineAntimicrob Agents Chemother200448349850715328117
   PubMed Web of Science ®Google Scholar
• ThongsawatSLaiCLGaneGTelbivudine displays consistent antiviral efficacy across patient subgroups for the treatment of chronic hepatitis B: results from the globe studyJ Hepatol200644S4916360232
   PubMed Web of Science ®Google Scholar
• VilletSPichoudCOllivetASequential antiviral therapy leads to the emergence of multiple drug resistant hepatitis B virusHepatology200542581A
   Web of Science ®Google Scholar
• WongDKHCheungAMO’RourkeKEffect of Alpha-Interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysisAnn Intern Med1993119312238328741
   PubMed Web of Science ®Google Scholar
• YimHJHussainMLiuYEvolution of multi-drug resistant hepatitis B virus during sequential therapyHepatology2006447031216941700
   PubMed Web of Science ®Google Scholar
• YurdaydinCSollanoJHadziyannisSJEntecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory HBeAg (+) chronic hepatitis B patients (ETV-026)J Hepatol200644S36
   Web of Science ®Google Scholar